SCHEMBL6792441

SCHEMBL6792441

CC1(C(O)c2ccc(-c3cccc(N)c3)cc2)NC(=O)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.40
MAOA P21397 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CA12 O43570 1/20 0.38
MCL1 Q07820 1/20 0.35
CYP17A1 P05093 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP19A1 P11511 2/20 0.35
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
MMP2 P08253 2/20 0.34
MMP9 P14780 2/20 0.34
MMP8 P22894 2/20 0.34
ADAMTS7 Q9UKP4 1/20 0.33
DHODH Q02127 1/20 0.33
PARP1 P09874 1/20 0.33
BRD4 O60885 1/20 0.33
PDPK1 O15530 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8339982 0.86 PGR (0.41) MMP2MMP9MMP8ADAMTS7DHODH
SCHEMBL6791227 0.85 MMP2 (0.41) CYP3A4MMP2MMP9MMP8PTGS2
SCHEMBL6791153 0.85 MMP2 (0.41) CYP3A4MMP2MMP9MMP8PTGS2
SCHEMBL6789361 0.85 MMP2 (0.41) CYP3A4MMP2MMP9MMP8PTGS2
SCHEMBL6835790 0.85 FFAR1 (0.41) MMP2MMP9DHODH
SCHEMBL6792382 0.83 PGR (0.48) DHODHBRD4
SCHEMBL6795889 0.82 CYP19A1 (0.35) CYP19A1MMP2MMP9
SCHEMBL6794482 0.82 PGR (0.49) MMP2
SCHEMBL6792279 0.82 MMP2 (0.54) TDP2MMP2MMP9MMP8
Ammonia Solution, Strong SCHEMBL6793015 0.81 CYP19A1 (0.34) CYP19A1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 TDP2 2225/4885MAOA 185/4885CA1 362/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 TDP2 3806/4885MAOA 220/4885CA1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.